Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Net Margin (2016 - 2025)

Amphastar Pharmaceuticals has reported Net Margin over the past 13 years, most recently at 31.9% for Q4 2025.

  • Quarterly results put Net Margin at 31.9% for Q4 2025, up 865.0% from a year ago — trailing twelve months through Dec 2025 was 18.35% (down 426.0% YoY), and the annual figure for FY2025 was 18.35%, down 426.0%.
  • Net Margin for Q4 2025 was 31.9% at Amphastar Pharmaceuticals, up from 9.04% in the prior quarter.
  • Over the last five years, Net Margin for AMPH hit a ceiling of 31.9% in Q4 2025 and a floor of 81.55% in Q4 2023.
  • Median Net Margin over the past 5 years was 18.64% (2023), compared with a mean of 9.31%.
  • Biggest five-year swings in Net Margin: crashed -8862bps in 2022 and later skyrocketed 10481bps in 2024.
  • Amphastar Pharmaceuticals' Net Margin stood at 19.57% in 2021, then plummeted by -453bps to 69.05% in 2022, then dropped by -18bps to 81.55% in 2023, then skyrocketed by 129bps to 23.26% in 2024, then skyrocketed by 37bps to 31.9% in 2025.
  • The last three reported values for Net Margin were 31.9% (Q4 2025), 9.04% (Q3 2025), and 17.79% (Q2 2025) per Business Quant data.